• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病史对经皮冠状动脉介入治疗后冠状动脉支架内再狭窄的预测价值

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention.

作者信息

Hou Ling, Su Ke, Zhao Jinbo, Li Yuanhong

机构信息

Department of Central Hospital of Tujia and Miao Autonomous Prefecture, Hubei University of Medicine, Shiyan, Hubei Province, People's Republic of China.

Cardiovascular Disease Center, Central Hospital of Tujia and Miao Autonomous Prefecture, Hubei University of Medicine, Enshi, Hubei Province, People's Republic of China.

出版信息

Int J Gen Med. 2023 Aug 31;16:3977-3984. doi: 10.2147/IJGM.S427425. eCollection 2023.

DOI:10.2147/IJGM.S427425
PMID:37670929
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10476650/
Abstract

OBJECTIVE

Chronic obstructive pulmonary disease (COPD) is a prevalent chronic respiratory disease that poses a significant health risk to individuals. Patients with COPD are predisposed to a higher incidence of coronary artery disease (CAD) than the general population. This study aims to investigate the correlation between COPD and the incidence of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI).

METHODS

This study retrospectively analyzed the clinical data and laboratory test results of patients who underwent PCI at our hospital between January 2018 and December 2021 to investigate the relationship between COPD and drug-Eluting Stents (DES) postoperative ISR. We employed the best subset method to select the most suitable combination of predictive factors, utilizing the data, and verified the precision of the model by means of internal validation. We ultimately assessed the performance of the prediction model using an ROC curve.

RESULTS

The research indicates that COPD is an independent risk factor for ISR after PCI (OR=2.437, 95% CI [1.336, 4.495], P=0.004). The analysis revealed an area under the receiver operating characteristic (ROC) curve of 0.783 for the training group and 0.705 for the testing group, indicating a model fitting for both groups (both > 0.5).

CONCLUSION

COPD history is a dependable predictor of stent restenosis post percutaneous coronary intervention.

摘要

目的

慢性阻塞性肺疾病(COPD)是一种常见的慢性呼吸道疾病,对个体健康构成重大风险。与普通人群相比,COPD患者更容易患冠状动脉疾病(CAD)。本研究旨在探讨COPD与经皮冠状动脉介入治疗(PCI)后支架内再狭窄(ISR)发生率之间的相关性。

方法

本研究回顾性分析了2018年1月至2021年12月在我院接受PCI治疗的患者的临床资料和实验室检查结果,以研究COPD与药物洗脱支架(DES)术后ISR之间的关系。我们采用最佳子集法选择最合适的预测因素组合,并利用这些数据通过内部验证来验证模型的准确性。我们最终使用ROC曲线评估预测模型的性能。

结果

研究表明,COPD是PCI术后ISR的独立危险因素(OR = 2.437,95% CI [1.336, 4.495],P = 0.004)。分析显示,训练组的受试者操作特征(ROC)曲线下面积为0.783,测试组为0.705,表明两组模型拟合良好(均>0.5)。

结论

COPD病史是经皮冠状动脉介入治疗后支架再狭窄的可靠预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/141a744b5bd7/IJGM-16-3977-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/052c5c9ae035/IJGM-16-3977-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/d3cc0a298b16/IJGM-16-3977-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/141a744b5bd7/IJGM-16-3977-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/052c5c9ae035/IJGM-16-3977-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/d3cc0a298b16/IJGM-16-3977-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/463c/10476650/141a744b5bd7/IJGM-16-3977-g0003.jpg

相似文献

1
Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention.慢性阻塞性肺疾病史对经皮冠状动脉介入治疗后冠状动脉支架内再狭窄的预测价值
Int J Gen Med. 2023 Aug 31;16:3977-3984. doi: 10.2147/IJGM.S427425. eCollection 2023.
2
A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis.预测经皮冠状动脉介入治疗患者支架内再狭窄风险的列线图:基于人群的分析
Int J Gen Med. 2022 Mar 3;15:2451-2461. doi: 10.2147/IJGM.S357250. eCollection 2022.
3
FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.成纤维细胞生长因子 23 与内分泌和代谢失调、心脏和肾脏功能恶化、炎症水平、狭窄程度相关,可独立预测经皮冠状动脉介入治疗(PCI)置入药物洗脱支架后冠心病患者的支架内再狭窄风险。
BMC Cardiovasc Disord. 2021 Jan 7;21(1):24. doi: 10.1186/s12872-020-01839-w.
4
Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.二代药物洗脱支架置入术后三血管病变患者血运重建和支架内再狭窄的危险因素:回顾性分析。
BMC Cardiovasc Disord. 2021 Sep 17;21(1):446. doi: 10.1186/s12872-021-02259-0.
5
The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.CHA2DS2-VASc评分对药物洗脱支架植入患者支架内再狭窄的预测价值
Int J Gen Med. 2023 Jan 5;16:69-76. doi: 10.2147/IJGM.S391312. eCollection 2023.
6
Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.中国南方人群经皮冠状动脉介入治疗后支架内再狭窄的发生率及危险因素。
Eur J Med Res. 2022 Jan 22;27(1):12. doi: 10.1186/s40001-022-00640-z.
7
Association of serum apoA-I with in-stent restenosis in coronary heart disease.血清载脂蛋白 A-I 与冠心病支架内再狭窄的相关性。
BMC Cardiovasc Disord. 2022 Aug 4;22(1):355. doi: 10.1186/s12872-022-02762-y.
8
The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.血清内脂素预测药物洗脱支架内再狭窄的价值。
Clin Chim Acta. 2018 Apr;479:20-24. doi: 10.1016/j.cca.2018.01.004. Epub 2018 Jan 3.
9
Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者支架内再狭窄风险预测列线图的建立与验证。
BMC Cardiovasc Disord. 2021 Sep 14;21(1):435. doi: 10.1186/s12872-021-02255-4.
10
Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.首次药物洗脱支架植入术后2年内老年冠心病合并2型糖尿病患者支架内再狭窄相关危险因素的调查
Front Cardiovasc Med. 2022 May 20;9:837330. doi: 10.3389/fcvm.2022.837330. eCollection 2022.

引用本文的文献

1
Catlet scoring system as a new predictor for in-stent restenosis in patients with chronic coronary artery disease undergoing percutaneous coronary intervention with drug-eluting stent.卡特利评分系统作为接受药物洗脱支架经皮冠状动脉介入治疗的慢性冠状动脉疾病患者支架内再狭窄的一种新预测指标。
J Cardiothorac Surg. 2025 Jan 29;20(1):106. doi: 10.1186/s13019-025-03349-2.

本文引用的文献

1
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.全球慢性阻塞性肺疾病倡议 2023 年报告:GOLD 执行摘要。
Eur Respir J. 2023 Apr 1;61(4). doi: 10.1183/13993003.00239-2023. Print 2023 Apr.
2
Prognostic value of Intermountain Risk Score for short- and long-term mortality in patients with cardiogenic shock.Intermountain 风险评分对心源性休克患者短期和长期死亡率的预后价值。
Coron Artery Dis. 2023 Mar 1;34(2):154-159. doi: 10.1097/MCA.0000000000001219. Epub 2023 Jan 4.
3
Association of Coronary Artery Severity and Late In-Stent Restenosis: An Angiographic Imaging Study.
冠状动脉狭窄程度与支架内晚期再狭窄的相关性:一项血管造影影像学研究。
Angiology. 2024 Feb;75(2):122-130. doi: 10.1177/00033197221150953. Epub 2023 Jan 6.
4
Long-Term Outcomes for Chinese COPD Patients After PCI: A Propensity Score Matched, Double-Cohort Study.中国慢性阻塞性肺疾病患者经皮冠状动脉介入治疗后的长期结局:一项倾向评分匹配的双队列研究。
Front Cardiovasc Med. 2022 Jun 9;9:827635. doi: 10.3389/fcvm.2022.827635. eCollection 2022.
5
Evaluation of Intermountain Risk Score for Short- and Long-Term Mortality in ST Elevation Myocardial Infarction Patients.评估 Intermountain 风险评分对 ST 段抬高型心肌梗死患者短期和长期死亡率的影响。
Angiology. 2023 Apr;74(4):357-364. doi: 10.1177/00033197221105753. Epub 2022 May 29.
6
Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States.美国冠状动脉支架植入术后再狭窄的趋势和结果。
J Am Coll Cardiol. 2020 Sep 29;76(13):1521-1531. doi: 10.1016/j.jacc.2020.08.002.
7
Recurrent Drug-Eluting Stent In-Stent Restenosis: A State-of-the-Art Review of Pathophysiology, Diagnosis, and Management.药物洗脱支架内再狭窄的现状:病理生理学、诊断和治疗的最新综述。
Cardiovasc Revasc Med. 2020 Sep;21(9):1157-1163. doi: 10.1016/j.carrev.2020.01.005. Epub 2020 Jan 10.
8
The predictive value of age, creatinine, ejection fraction score for in-hospital mortality in patients with cardiogenic shock.年龄、肌酐、射血分数评分对心源性休克患者院内死亡率的预测价值。
Coron Artery Dis. 2019 Dec;30(8):569-574. doi: 10.1097/MCA.0000000000000776.
9
Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.慢性阻塞性肺疾病(COPD)代谢综合征(MetS)的病理生物学机制:临床意义和治疗策略。
Pharmacol Ther. 2019 Jun;198:160-188. doi: 10.1016/j.pharmthera.2019.02.013. Epub 2019 Feb 26.
10
Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?COPD 中的心理共病:针对全身炎症,对两者都有益?
Eur J Pharmacol. 2019 Jan 5;842:99-110. doi: 10.1016/j.ejphar.2018.10.001. Epub 2018 Oct 15.